Increased plasma-6-oxo-PGF1-alpha but normal PGI2 half-life in patients with maxillo-facial tumors.

Abstract

In 56 patients with histologically verified maxillo-facial cancer the plasma 6-oxo-PGF1-alpha was determined prior surgery using a specific RIA and the double antibody technique. Furthermore, the half-life of synthetic PGI2 has been assessed via the disappearance curve of biological activity on platelet aggregation inhibition. Part of the patients has been… (More)

Topics

Cite this paper

@article{Porteder1987IncreasedPB, title={Increased plasma-6-oxo-PGF1-alpha but normal PGI2 half-life in patients with maxillo-facial tumors.}, author={H. Porteder and Martin Matejka and G. Kment and Amanda Nell and Hannelore Sinzinger}, journal={Progress in clinical and biological research}, year={1987}, volume={242}, pages={123-9} }